Privately-held UK-based T cell receptor (TCR) specialist Immunocore has announced positive Phase III data from the IMCgp100-202 clinical trial of tebentafusp.
The firm is testing the novel bispecific protein in uveal melanoma, a rare and aggressive form of eye cancer which typically has a poor prognosis, and for which there is a high level of unmet medical need.
The trial met its primary endpoint of overall survival (OS) at the first pre-planned interim analysis. The OS hazard ratio (HR) in the intent-to-treat population favored tebentafusp (95%), over investigator’s choice, (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze